Pangaea Oncology, S.A. (BME:PANG)

Market Cap	59.78M
Revenue (ttm)	14.35M
Net Income (ttm)	-5.34M
Shares Out	34.36M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	322
Average Volume	403
Open	1.740
Previous Close	1.700
Day's Range	1.740 - 1.740
52-Week Range	1.470 - 1.800
Beta	0.07
RSI	48.03
Earnings Date	May 9, 2025

About Pangaea Oncology

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnost...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 149
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PANG

Financial Performance

In 2023, Pangaea Oncology's revenue was 9.95 million, an increase of 49.12% compared to the previous year's 6.68 million. Losses were -4.66 million, 71.7% more than in 2022.